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Hyperoxia but not AoX expression 
mitigates pathological cardiac 
remodeling in a mouse model of 
inflammatory cardiomyopathy
praveen K. Dhandapani  1,2, Isabel M. Begines-Moreno3, Gloria Brea-calvo  4, 
Ulrich Gärtner5, Thomas G. Graeber  6, Gerardo Javier Sanchez6, Rory E. Morty7, 
Kai Schönig8, Johanna ten Hoeve6, Astrid Wietelmann6, Thomas Braun6, Howard T. Jacobs  1,2 
& Marten Szibor  1,2
Constitutive expression of the chemokine Mcp1 in mouse cardiomyocytes creates a model of 
inflammatory cardiomyopathy, with death from heart failure at age 7–8 months. A critical pathogenic 
role has previously been proposed for induced oxidative stress, involving NADPH oxidase activation. 
To test this idea, we exposed the mice to elevated oxygen levels. Against expectation, this prevented, 
rather than accelerated, the ultrastructural and functional signs of heart failure. This result suggests 
that the immune signaling initiated by Mcp1 leads instead to the inhibition of cellular oxygen usage, for 
which mitochondrial respiration is an obvious target. To address this hypothesis, we combined the Mcp1 
model with xenotopic expression of the alternative oxidase (AOX), which provides a sink for electrons 
blocked from passage to oxygen via respiratory complexes iii and iV. Ubiquitous AoX expression 
provided only a minor delay to cardiac functional deterioration and did not prevent the induction 
of markers of cardiac and metabolic remodeling considered a hallmark of the model. Moreover, 
cardiomyocyte-specific AOX expression resulted in exacerbation of Mcp1-induced heart failure, and 
failed to rescue a second cardiomyopathy model directly involving loss of cIV. Our findings imply that 
mitochondrial involvement in the pathology of inflammatory cardiomyopathy is multifaceted and 
complex.
Monocyte chemoattractant protein 1 (Mcp1), a small cytokine of the chemokine family, is expressed and secreted 
by pathogen-infected or damaged cells, to activate appropriate immune responses (see relevant reviews1,2). Its 
immediate effect is to promote the infiltration of immune cells, principally monocytes, and facilitate their activa-
tion as phagocytes able to attack pathogens and remove debris. Although the exact sequence of events is not fully 
understood, secondary signaling from immune cells promotes repair, stress-resistance and tissue remodeling, 
as appropriate. In the case of a cardiac infarct resulting from localized ischemia, the responses induced in this 
manner by Mcp1 have been shown to facilitate the survival and repair of the surrounding tissue, as well as revas-
cularization and scar formation3.
Accordingly, constitutive over-expression of Mcp1 in cardiomyocytes in the young (8–12 week-old) mouse 
was shown to protect against some of the consequences of myocardial infarct, notably by limiting the extent of 
scar formation and adverse tissue remodeling, in specific pathological paradigms4,5. However, in other experi-
ments Mcp1 was found to be detrimental to recovery after a cardiac ischemic episode, based on the phenotypic 
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improvement brought about by expressing a truncated, dominant-negative version of human MCP16. Mcp1 and 
other cytokines have been implicated in human heart failure7, where their chronic activation leads to an inflam-
matory crisis, with generalized remodeling that eventually compromises contractile function.
The mouse line constitutively overexpressing Mcp1 in adult cardiomyocytes (referred to hereafter as ‘the Mcp1 
mouse’) shows progressive phenotypic deterioration, involving myocardial infiltration by monocytes that fail to 
differentiate properly, leading to an inflammatory crisis that is ultimately fatal8. The Mcp1 mouse is therefore an 
animal model for several different aspects of cardiac pathology, including ischemic preconditioning5, inflamma-
tory cardiomyopathy and chronic heart failure due to adverse remodeling of the myocardium. The initial phase 
of tissue remodeling can be considered to be beneficial, following tissue damage due to ischemia or infection. 
This process is envisaged to switch metabolism at the borders of a damaged area of the myocardium to a lower 
energy, more glycolytic state, preserving tissue integrity during repair. On the other hand, chronic inflammatory 
signaling initiated by Mcp1 results in adverse remodeling of the entire myocardium. Studies in a cardiac myoblast 
cell-line have also suggested a direct effect of Mcp1 on cardiomyocytes, mediated by Mcp1-inducible protein 
(MCPIP), which elicits the activation of NADPH oxidase at the cell membrane, promoting autophagy and even-
tual cell death due to the resulting excessive ROS production9.
In order to test whether such an oxidative crisis can explain the pathology of the Mcp1 mouse, we exposed 
the mice to a hyperoxic regime, which would be predicted to synergize with NADPH oxidase activation. Against 
expectation, this treatment did not accelerate the inflammatory crisis, but instead conferred protection against it. 
The result suggested that the inflammatory crisis involved inhibition of the major oxygen-using machinery of the 
cell, namely mitochondrial oxidative phosphorylation (OXPHOS).
To test the involvement of OXPHOS, we made use of a mouse model expressing the alternative oxidase (AOX) 
from Ciona intestinalis10. AOX is absent from mammals but is found in most other taxa. It serves as a by-pass 
of the terminal steps of respiratory electron transfer from ubiquinol (CoQ) to oxygen, catalyzed by OXPHOS 
complex III (cIII, ubiquinol:cytochrome c oxidoreductase) and cIV (cytochrome c oxidase). In contrast to cIII 
and cIV, AOX is a non-proton-motive enzyme, for which reason its engagement also leads to a substantial drop in 
ATP yield. Importantly, AOX only becomes active under conditions where the reduction state of its primary sub-
strate, ubiquinol, surpasses a certain threshold, typically with around 30–40% of it accumulating in the reduced 
form11–13. Thus, AOX is only engaged when the standard respiratory chain is inhibited or overloaded downstream 
of ubiquinol reduction, and thus its expression does not generate a global ‘short-circuit’ in mitochondrial energy 
metabolism.
In accordance with this, mice expressing AOX under the strong, ubiquitously active CAG promoter are 
viable, and exhibit essentially no physiological differences from wild-type mice when reared under standard, 
non-stressful conditions10,14. Nevertheless, in the face of specific pathological stresses, such as exposure to cya-
nide, a poison targeted on cIV10,14, AOX-expressing mice show spectacular resistance. They also resist the car-
diotoxicity of a point mutation in an assembly factor for cIII15, and the lethal inflammatory crisis induced by 
lipopolysaccharide16. These two findings have obvious potential relevance to the Mcp1 mouse: the first because a 
cardiomyopathy was rescued, the second because AOX was able to attenuate macrophage activation due to res-
piratory chain inhibition and succinate overload. A similar process should be driven by chronic Mcp1 expression 
in the heart, which AOX should be able to alleviate by the same mechanism.
To address the issue of cell-type specificity we made use of two murine AOX models: the one already 
described10, which expresses AOX ubiquitously, and a second model that we constructed, enabling us to express 
AOX specifically in cardiomyocytes. This allowed us to assess separately whether AOX is able to overcome the 
lethal phenotype induced by directly crippling cIV in cardiomyocytes. Our findings, presented below, indicate 
that any role of mitochondrial dysfunction in the inflammatory crisis provoked by chronic Mcp1 overexpression 
is primarily in cells other than cardiomyocytes.
Results
The inflammatory crisis induced by Mcp1 can be mitigated by hyperoxia. In the Mcp1-
overexpressing heart, tissue remodeling was marked by a progressive disruption of the tissue, involving deg-
radation of the intracellular actomyosin network (Fig. S1A), disorganization of mitochondria, extensive 
intracellular vacuolation, especially in the perinuclear region (Fig. 1B), and induction of the autophagic marker 
LC3 (Fig. S1A). To test predictions of the previously elaborated hypothesis, that this involves an oxidative crisis in 
cardiomyocytes, produced by the activation of NADPH oxidase, we subjected Mcp1 mice to a hyperoxic regime 
(Fig. 1A). If the hypothesis is correct, hyperoxia should potentiate oxygen-dependent reactions and accelerate the 
loss of cardiac function. However, we instead observed a spectacular improvement, both at the ultrastructural 
(Fig. 1B) and functional (Fig. 1C) levels, consistent with the idea that oxygen levels over-ride rather than syner-
gize with the effects of Mcp1 overexpression.
Conditionally activatable AOX can be specifically expressed in mouse heart. The effect of hyper-
oxia suggests a completely different explanation for the phenotype produced by Mcp1 overexpression, namely 
that Mcp1 provokes the inhibition of the major oxygen-dependent pathway of cells, mitochondrial respiration. 
Respiratory inhibition at or beyond the level of cIII has already been implicated in macrophage activation16. 
Furthermore, since OXPHOS is the major producer of cellular ATP, its inhibition in cardiomyocytes could also 
be postulated to be part of a machinery that switches metabolism to a tissue-protective, more glycolytic state. This 
would result in adverse remodeling of the entire tissue, if left unchecked.
To test this idea, we switched to genetic models, which offer the possibility of probing mitochondrial involvement 
in Mcp1-induced pathology in different cell-types (whereas hyperoxia obviously affects all of them). To complement 
the use of the AOX mouse described above10 (‘global AOX’), we constructed a second mouse line (‘SNAPf-AOX’) 
containing a version of the AOX transgene placed downstream of a floxed copy of the coding sequence of the 
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SNAP-tag peptide17. To prevent readthrough expression of AOX, the SNAP-tag cassette included three, reiterated 
copies of the poly(A) addition sequence from SV40 (Fig. 2A). The entire construct was inserted at the Rosa26 locus 
under the control of the chimeric CAG promoter, directing ubiquitous expression, as for global AOX. However, 
expression is initially only of the SNAP tag. Activation of AOX expression requires Cre-mediated recombination. 
The insertion was verified in the donor ES cell-line by Southern hybridization and sequencing, then tracked subse-
quently by PCR (see Methods). Expression of the SNAP-tag peptide was verified in hemizygous SNAPf-AOX mice 
in all tissues tested by Western blot (Fig. 2B), whilst AOX protein was undetectable. When hemizygous SNAPf-AOX 
mice were crossed with a line hemizygous for ACTB-Cre, directing Cre recombinase expression ubiquitously under 
the control of the β-actin promoter, double transgenic progeny now expressed AOX in all tissues tested, whilst 
SNAP-tag expression was undetectable (Fig. 2B). Crossing hemizygous or homozygous SNAPf-AOX mice with 
mice expressing Cre recombinase specifically in adult cardiomyocytes under the control of the Myh6 promoter 
(Myh6-cre) yielded double-transgenic progeny expressing AOX uniquely in heart (Fig. 2C). Note that the SNAP tag 
continued to be expressed in the heart in these mice at a lower level, reflecting the fact that heart tissue contains other 
cell-types than just cardiomyocytes, as well as possible mosaicism due to incomplete Cre-mediated recombination-
AOX does not rescue lethal heart failure due to Mcp1 overexpression in cardiomyocytes. We 
initially tracked the survival of mice overexpressing Mcp1 in cardiomyocytes, with or without the additional pres-
ence of global or cardiomyocyte-specific AOX, alongside appropriate controls. Male Mcp1 mice died between 25 
and 35 weeks of age (Fig. 3A, red trace). Global AOX expression did not alter this, nor did the Myh6-cre inducer 
used to activate AOX specifically in cardiomyocytes (Fig. 3A, green and grey traces, respectively), although 
Myh6-cre, both alone (purple trace) or together with SNAPf-AOX (orange trace, ‘cardio AOX’), did affect survival 
starting much later, around 40 weeks, as previously reported18. However, cardio AOX in combination with Mcp1 
produced a clear acceleration of the lethal phenotype, with double-expressor mice dying between 16–25 weeks 
of age (blue trace). Cardiac parameters followed a similar pattern. Whilst mean diastolic and systolic volumes in 
Mcp1-overexpressing mice showed only minor deviations from the controls (Fig. 3B), computed ejection frac-
tions (EF, Fig. 3C) revealed a progressive deterioration in heart contractile function in all Mcp1-overexpressing 
groups. This was already evident at 12 weeks, although both global (green diamonds) and cardio AOX (blue cir-
cles) did produce a small functional improvement at this time point, compared with Mcp1 overexpressors alone 
(red squares). By 16 weeks this was no longer statistically significant for global AOX. For Mcp1 mice combined 
with cardio AOX the EF at 16 weeks was clearly decreased compared with the other groups (Fig. 3C, blue circles), 
and by 20 weeks the paucity of survivors prevented a meaningful analysis. At 16 weeks, there was no evidence of 
cardiotoxicity in the mice expressing only cardiomyocyte-specific AOX but not Mcp1 (orange triangles). There 
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Figure 1. Heart failure due to Mcp1 overexpression in heart is suppressed by hyperoxia. (A) Summary of the 
experimental set-up. (B) Transmission electron micrographs of heart tissue from 26-week old animals of the 
indicated genotypes and treatments. Yellow scale-bars – 2 μm, N – nucleus, red arrows indicate structures 
resembling autophagosomes. The gross tissue disruption produced by Mcp1 overexpression in the heart is 
strongly mitigated by hyperoxia. (C) Cardiac ejection fraction (EF, %) of mice of the indicated genotypes (wt 
– wild-type, Mcp1 – overexpressing Mcp1 in cardiomyocytes), data shown as mean ± SD, n ≥ 5 for all groups. 
Horizontal lines denote significantly different groups (two-way ANOVA, post hoc Tukey HSD test, p < 0.05; see 
Table S1). Computed from the data shown in Fig. S1C,D, using MRI conducted at 26 weeks.
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were also no significant differences in left ventricular mass (Fig. S2A), total body weight (Fig. S2B) or in treadmill 
performance (Fig. S2C) between wild-type and Mcp1 mice, regardless of AOX expression, at 12 or 16 weeks.
AOX does not alter the switch to a fetal-like gene expression program in Mcp1 mice. To evalu-
ate the combined effects of Mcp1 over-expression and AOX on heart physiology, we next analyzed the expression 
at the RNA level of a set of key genes involved in cardiomyocyte function, metabolic adaptation and stress signal-
ing, serving as markers of the remodeling process. We focused on the 12-week time point, at which we had picked 
up the transient protective effect by AOX. We first verified the overexpression of Mcp1 (Fig. 4), which was upregu-
lated by >4 orders of magnitude. All other changes seen were common to the three Mcp1-overexpressing groups, 
distinguishing them from wild-type and other controls (Fig. 4), but revealing no significant effects attributable 
to AOX. The mRNA for the immunomodulatory cytokine IL10 was induced several-fold, whilst cardiomyocyte 
markers indicated the expected shift towards a fetal-like gene expression pattern, with upregulation of Myh7, 
downregulation Myh6 and of Gata4, the transcription factor involved in the switch between them. This was 
accompanied by changes reflecting a more anaerobic metabolism, with downregulation of the hypoxia-inducible 
cytokine Egln3, of Sod2, responsible for detoxifying mitochondrial superoxide, and of Mtor. Two cytokines, Fgf21 
and Gdf15, that have been linked to the signaling of mitochondrial dysfunction, as well as to other metabolic 
stresses and inflammation, were strongly induced, but this too was unaffected by AOX.
AOX has only minimal effects on mitochondrial downregulation in Mcp1 mice. The induction of 
Fgf21 and Gdf15 led us to investigate mitochondrial structure and function in the Mcp1 mice in more detail. Based 
on electron microscopy, Mcp1 overexpression (Fig. 5A, red marker) resulted in little or no disorganization of the 
intracellular actomyosin network at the 12-week time point. Mitochondria appeared almost normal, although the 
density of cristae appeared to be decreased, and we observed the presence of nearby structures that we interpret as 
secondary lysosomes, which were not seen in the hearts of Mcp1 mice also expressing global AOX (Fig. 5A, green 
marker). Respirometry revealed a clear decrease in the respiratory capacity of heart mitochondria from Mcp1 mice 
(Fig. 5B). Oxygen consumption on cI-linked substrates was significantly decreased at both 12 and 16 weeks (Fig. 5B). 
cII-linked respiration was only mildly affected at both time points, but global AOX expression significantly increased 
it, with cI-linked respiration showing a similar trend. The decreased respiratory capacity of Mcp1-overexpressing 
heart reflected a generalized, if small decrease in the abundance of respiratory chain subunits (Fig. 5C – see quanti-
tation by densitometry in Fig. S3A), although this was less evident at 16 weeks (Fig. S3B). At both time points, AOX 
expression had no clear impact (Figs 5C and S3A,B). These various changes can again be interpreted as markers of 
the remodeling process, upon which AOX has only a minor and transient impact.
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Figure 2. SNAPf-AOX mice express AOX when activated by tissue-specific recombination. (A) Schematic map 
of the SNAPf-AOX insert at the Rosa26 locus (flanking regions, grey). The SNAP-tag coding sequence (black), 
followed by a threefold reiteration of the SV40 poly(A) signal (SV40 pA, orange) is flanked by loxP sites (green, 
directionality as shown). Cre-mediated recombination removes the entire SNAP-tag cassette, juxtaposing the 
synthetic CAG promoter (blue) with the AOX coding sequence (yellow), followed by the β-globin intron and 
poly(A) signal (β-G intron/pA, white). (B,C) Western blots of protein extracts from tissues of progeny mice of 
the indicated genotypes, from crosses between SNAPf-AOX and hemizygous mice expressing cre recombinase 
under the control of (B) the ubiquitously active β-actin (ACTB-cre) or (C) cardiomyocyte-specific myosin 
heavy-chain 6 (Myh6-cre) promoters. Tissues denoted as follows: H – heart, Lu – lung, Li – liver, B – brain, K – 
kidney, S – spleen, P – pancreas, Mt – thigh muscle, Mm – masseter muscle, E – eye, T – testis. Molecular weight 
of the detected polypeptides (kDa) inferred from the electrophoretic mobility of markers.
5Scientific RepoRtS |         (2019) 9:12741  | https://doi.org/10.1038/s41598-019-49231-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Cardiomyocyte-specific AOX produces metabolic changes in Mcp1 mice. AOX contributes appre-
ciably to electron flow only when the ratio of reduced to oxidized quinone rises above ~0.4. To check whether the 
decreased respiratory capacity of mitochondria from Mcp1- overexpressing heart had resulted in such a build-up, 
we measured the amounts of reduced and oxidized CoQ9 and CoQ10 in heart tissue by fast lipid extraction and 
HPLC. (Note that mice use both CoQ9 and CoQ10 in OXPHOS, although the former predominates). In the case of 
CoQ10 (Fig. 5D), there was a significant shift towards the reduced form in Mcp1-overexpressing heart, which was 
not altered by global AOX. In contrast, cardiomyocyte-specific AOX resulted in a decreased ratio of CoQ10(red)/
CoQ10(ox) that was almost restored to that of wild-type (Fig. 5D). CoQ9 followed a similar trend (Fig. S3C), 
although the differences did not reach significance, and their extent was quantitatively less than for CoQ10. In all 
Mcp1 groups there was a small but significant increase in the glycolytic enzyme GAPDH (Fig. S3A), but induction 
of the autophagic marker LC3b-II was minimal (Fig. S3E,F) and ‘oxyblot’ revealed no evidence for widespread 
oxidative damage to proteins (Fig. S3G). None of these parameters was systematically affected by AOX. However, 
analysis of the global metabolome using a labeled glucose tracer did reveal an effect of cardiomyocyte-specific 
AOX already at 12 weeks. Principal component analysis (PCA) of the labeled heart metabolites (Fig. 6) showed 
a clear difference between control and Mcp1 mice, with the global AOX + Mcp1 mice overlapping with Mcp1 
alone, but slightly shifted on the plot in the direction of wild-type, consistent with its minor, transient effect on 
mitochondria (Fig. 5). Mcp1 mice expressing cardio AOX were more distinct from all others (Fig. 6, blue circles), 
consistent with an early metabolic crisis, prefiguring the contractile dysfunction that was observed at 16 weeks 
(Fig. 3C). For a fuller explanation of the PCA see Fig. S4 and the associated Tables S5 and S6.
Figure 3. AOX expression modifies the cardiac phenotype of Mcp1 overexpressing mice. (A) Survival curves 
of mice of the indicated genotypes (wt – wild-type, Mcp1 – overexpressing Mcp1 in cardiomyocytes under the 
control of the Myh6 promoter; global AOX – expressing AOX constitutively; cardio AOX – expressing AOX 
specifically in cardiomyocytes, after activation of SNAPf-AOX by Myh6-cre, Myh6-cre – expressing only cre 
in adult cardiomyocytes, and combinations as shown, n ≥ 10 for all groups except those including Myh6-cre, 
where n ≥ 5). The survival curve for Mcp1 plus cardiomyocyte-specific AOX was significantly different from 
that of Mcp1 alone, or together with global AOX (p < 0.0001, Log-rank (Mantel-Cox) or Gehan-Breslow-
Wilcoxon test, see Table S2). (B) Systolic and diastolic volume of the cardiac left ventricle (LV) of mice of 
the indicated genotypes, measured by ultrasound at 12 and 16 weeks, as indicated (means ± SD, n ≥ 5 for all 
groups). (C) Cardiac ejection fraction (EF, %) computed for individual mice of the indicated genotypes and 
ages, means ± SD. Horizontal lines marked with asterisks indicate significant differences (one-way ANOVA 
within an age point, applying Tukey’s post hoc HSD test; *, **, ***p < 0.05, 0.01, 0.001, respectively).
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AOX is unable to rescue heart failure caused directly by cIV deficiency. The failure of AOX to 
provide a durable, functional rescue of the Mcp1-induced phenotype, and even to exacerbate it when expressed 
specifically in cardiomyocytes, can have various possible explanations. Despite the global downregulation of res-
piratory chain proteins and capacity, the data of Fig. 5B,C suggest that a key target could be cI, for which AOX 
does not substitute. Another possibility is that mitochondrial downregulation, although part of the tissue remod-
eling process, is only incidental to the pathology. The aggravation of the phenotype due to cardiomyocyte-specific 
AOX may also reflect the underlying dependence of contractile function on ATP. AOX, once activated, should 
restore redox homeostasis, as evidenced by the normalization of CoQ10 oxidation, (Fig. 5D), but will not replenish 
ATP, instead depleting it further. To test the extent to which AOX can functionally replace cIII + cIV in cardi-
omyocytes, we combined it with a second model in which heart failure is a direct result of mitochondrial cIV 
deficiency, brought about by cardiomyocyte-specific knockout of Cox10, a biosynthetic enzyme for heme a, an 
essential prosthetic group of cIV. Using Myh6-cre, we first confirmed that cardiomyocyte-specific knockout of 
Cox10 was lethal at an early time point (none of the animals that survived till weaning was homozygous for the 
floxed Cox10 allele and positive for Myh6-cre, out of 45 live pups, Table S7, p < 0.01, chi-squared test with Yates’ 
correction). We then combined cardiomyocyte-specific Cox10 knockout with cardiomyocyte-specific AOX acti-
vation, producing essentially the same result (zero animals homozygous both for the floxed allele of Cox10 and for 
Myh6-cre, whether with or without AOX, out of 80 live pups, Table S7, p < 0.001, chi-squared test, Yates’ correc-
tion). We followed a small cohort day-by-day from birth, to determine the exact timing of death (Fig. 7A), which 
was the same for the AOX-positive and -negative Cox10 knockout mice. Mice with heterozygous Cox10 knockout 
in cardiomyocytes, both with and without AOX, were then studied further, although this is complicated by the 
late-onset cardiotoxic effect of Myh6-cre on its own18. Cox10 heterozygosity produced an apparent slight allevia-
tion of the eventual lethality of Myh6-cre (Fig. 7B), whilst AOX expression exacerbated it (Fig. 7B). Conversely, at 
12 weeks, heterozygous knockout of Cox10 in cardiomyocytes caused a significant detriment to heart contractile 
function as measured by ejection fraction (Fig. 7C), which was mildly alleviated by AOX co-expression. By 24 
weeks, this alleviation was no longer apparent, but contractile function at that time point was impaired in all 
groups expressing Myh6-cre (Fig. 7C). In conclusion, AOX provided little or no functional benefit as a replace-
ment for cIII + cIV.
Figure 4. Modification of gene expression due to Mcp1/AOX expression. qRTPCR analysis of levels of the 
indicated RNAs in cardiac left ventricle of 12-week old mice of the genotypes shown, in each case normalized to 
the value for wild-type (means ± SD, n = 5 for each genotype). Horizontal lines marked with asterisks indicate 
significant differences between wild-type and other groups (one-way ANOVA with Tukey post hoc HSD test; **, 
***p < 0.01, 0.001, respectively). For clarity, significant differences between other groups is not shown, but is 
summarized in full in Table S3.
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Discussion
In this study, we set out to test the involvement of oxygen metabolism in the inflammatory crisis unleashed by 
constitutive expression of Mcp1 in cardiomyocytes. Mcp1-induced heart failure was suppressed rather than exac-
erbated by hyperoxia, whilst AOX had little effect, and even accelerated the lethal phenotype when expressed only 
in cardiomyocytes. AOX was also unable to compensate the postnatal lethality of a severe cytochrome oxidase 
defect in cardiomyocytes. These findings have important implications for understanding the metabolic and func-
tional consequences of chronic inflammation in the heart.
Why did AOX fail to alleviate the phenotype of the Mcp1 mouse?. The beneficial effects of hyper-
oxia in the Mcp1 model (Fig. 1) refute the involvement of NADPH oxidase (or any other oxygen-dependent 
enzyme) in promoting adverse remodeling, and instead suggested mitochondrial inhibition as a mechanism. 
However, the negative effect of cardiomyocyte-specific AOX in the Mcp1 model, and its failure to compensate for 
the knockout of Cox10, imply that restoring or maintaining mitochondrial redox homeostasis in cardiomyocytes 
is insufficient to sustain contractile function. Rather, our findings point toward the importance of adequate ATP 
production, given that AOX-supported respiration abrogates proton-pumping at both cIII and cIV, leaving only 
Figure 5. Compromised mitochondrial functions in Mcp1 mice are minimally modified by AOX. Transmission 
electron micrographs of cardiac left ventricle from 12-week old animals of the indicated genotypes and 
treatments. Scale bars as indicated: bottom images represent higher magnification of portions of those shown 
in the top line. The dark inclusions in close proximity to mitochondria, seen in cardiomyocytes from the Mcp1-
overexpressing mice, are interpreted as secondary lysosomes. >12 such sections were analysed from mice of 
each genotype (2–3 sections from each of 2 blocks from 3 individuals). Multiple such inclusions were seen in 
the sections from Mcp1 mice, but not from controls or from mice expressing global AOX. Note also the less 
densely packed cristae in mitochondria from the Mcp1-overexressing mice, which was evident in all sections 
analysed. (B) Respirometry of mitochondrial suspensions from heart tissue of mice of the indicated genotypes, 
driven by cI- or cII-linked substrates as shown. (C) Representative Western blots of heart protein extracts from 
12-week old mice of the indicated genotypes, probed as shown. Note that each lane represents a sample from an 
individual mouse, analyzed on separate gels for different proteins. Approximately equal loading was confirmed 
by the use of a prestained gel system (see images from these gels in Fig. S3D). For each genotype, samples from 
five individual mice were analyzed, giving means ± SD of densitometric signal as shown in Fig. S3A. (D) HPLC 
analysis of ratio of reduced to oxidized CoQ10 in hearts from 12-week old mice of the indicated genotypes. 
Horizontal lines denoted by asterisk (*) indicate significant differences between groups (one-way ANOVA, with 
Tukey’s post hoc HSD test, p < 0.05, Table S4).
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cI as an energy-yielding step. In accord with the idea that a mostly glycolytic metabolism is sufficient to maintain 
cardiac development and function throughout the fetal period, Cox10 cardiac knockout pups were ostensibly 
indistinguishable from wild-type littermates. However, once exposed to an oxygen-rich atmosphere, they failed to 
thrive and died within 2–3 weeks postnatally, with AOX providing no benefit (Fig. 7A). Cardiomyocyte-specific 
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Figure 6. Cardiomyocyte-specific AOX expression alters cardiac metabolism of Mcp1 mice. Principal 
component analysis of metabolome data (13C-glucose tracer) from cardiac left ventricles of 12-week old mice of 
the indicated genotypes. The plot is based on 17 glucose metabolites that passed statistical filtering, corrected for 
low fractional contribution from the labelled glucose.
Figure 7. Minimal phenotypic modification by AOX, of Cox10 heart knockout. (A,B) Survival curves of mice 
of the indicated genotypes: Cox10−/− – cardiomyocyte-specific knockout of Cox10, i.e. mice were Cox10fl/
fl plus Myh6-cre+/−; Cox10−/− + cardio AOX – cardiomyocyte-specific knockout of Cox10 plus activation of 
SNAPf-AOX by Myh6-cre (both heterozygous); Myh6-cre – Myh6-cre+/− only, no cre – control mice lacking 
Myh6-cre, cardio AOX – cardiomyocyte-specific activation of SNAPf-AOX by Myh6-cre, both hemizygous; 
Cox10+/− – cardiomyocyte-specific heterozygous knockout of Cox10, i.e. mice were Cox10+/fl and Myh6-cre+/−; 
Cox10+/− + cardio AOX – cardiomyocyte-specific heterozygous knockout of Cox10, i.e. mice were Cox10+/fl 
and heterozygous for both Myh6-cre and SNAPf-AOX. n ≥ 6 for all groups. (C) Cardiac ejection fraction (EF, 
%) computed for individual mice of the indicated genotypes and ages, means ± SD, by echocardiography. 
Horizontal lines marked with asterisks indicate significant differences (one-way ANOVA within an age point, 
applying Tukey’s post hoc HSD test; *, **, ***p < 0.05, 0.01, 0.001, respectively).
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expression of AOX in the Mcp1 mouse, which is enzymatically engaged sufficiently to lower the ratio of reduced 
to oxidized ubiquinone (Fig. 5D), should also lower the energetic yield of OXPHOS. This alone may be suffi-
cient to exacerbate the contractile failure resulting from Mcp1-induced remodeling. Further analysis of the heart 
metabolome of the Mcp1 mice with and without cardio AOX may shed light on the processes by which the tissue 
responds to chronic inflammatory signaling combined with failing endogenous ATP supply.
A different possible explanation for the detrimental effect of cardiomyocyte-specific AOX in the Mcp1 mouse 
mirrors that elaborated earlier13 in the case of muscle-specific knockout of Cox15, another enzyme involved in 
heme a biosynthesis. In the Cox15 model, AOX expression was found to abolish ROS signaling consequent upon 
respiratory chain inhibition. In skeletal muscle, this signaling is required to recruit satellite cells to replace dam-
aged myofibrils. AOX therefore produced an exacerbation of the phenotype. Cardiac repair proceeds instead via 
an intracellular mechanism but if this also depends upon a mitochondrial ROS signal, e.g. elicited by oxygen in a 
tissue with compromised respiratory function due to chronic remodeling, cardiomyocyte-specific AOX expres-
sion would again be expected to negate it.
Mechanism of Mcp1-induced heart failure. Although Mcp1 is overexpressed only in cardiomyocytes 
in the Mcp1 mouse, it is a secreted cytokine that acts directly or indirectly on a variety of cell types, including 
(by definition) monocytes and other immune cells, as well as fibroblasts, endothelial cells and neighboring car-
diomyocytes. This complexity undoubtedly contributes to the apparently contradictory or biphasic nature of 
the Mcp1 response reported in the literature, which promotes vascularization and limits scar formation after 
an ischemic episode5, but eventually leads to catastrophic remodeling even in the absence of an external insult 
(Figs 1 and 3). Although the precise cell-type specificity of these processes is poorly understood, the models used 
in this study, are potentially informative. The effect of hyperoxia, given the failure of AOX to rescue, raises the 
possibility that direct oxygen-sensing in cardiomyocytes and/or other cells may act to negate immune-derived 
signals that would otherwise maintain the myocardium in a low-energy state during tissue repair, following an 
infectious or ischemic episode. Effective oxygen delivery could be a physiological cue that such repair is complete, 
and that cardiomyocytes can resume normal function. Productive versus adverse tissue modeling should reflect 
the balance of such signals, in which endogenous indicators of the state of the cardiomyocytes themselves should 
logically also play a part. The minimal effect of global AOX could therefore simply be a composite of a strongly 
positive effect to dampen inflammatory signaling from macrophages and a strongly negative effect arising from 
compromised ATP production in cardiomyocytes that just cancel one another out. To shed further light on this 
will require the use of combinatorial tissue expression, including the use of a macrophage-specific Cre to activate 
AOX expression19.
Note that our data do not address the question of the cell-type(s) upon which Mcp1 itself acts. The canonical 
targets of all chemokines are immune cells, so there is no a priori reason to invoke a direct effect on cardio-
myocytes. Our findings with AOX strongly imply that at least one other cell-type is involved in inducing the 
remodeling process leading to contractile failure, for which macrophages are the obvious candidates. To pin 
down whether Mcp1 has any direct effect upon cardiomyocytes would require further genetic modeling, such as 
cell-specific knockout of the Mcp1 receptor CCR2.
Other processes may influence global and cardiomyocyte-specific AOX phenotypes. There 
remain other possible explanations for the phenotypic difference between global AOX and cardiomyocyte-specific 
AOX expression in the Mcp1 mouse, which should be considered. One is that Myh6-cre is not sufficiently 
expressed in all cells to produce a uniform genomic rearrangement. In SNAPf-AOX mice also expressing 
Myh6-cre, some residual SNAP-tag expression was seen in heart (Fig. 2C), which is attributable to expression in 
other cell types than cardiomyocytes. If, however, the SNAPf-AOX insert in a minor fraction of cardiomyocytes 
were not recombinationally resolved, the myocardium would be a mosaic of AOX-positive and -negative cells. 
These would manifest different types of energetic metabolism, potentially compromising their ability to contract 
in unison. Mosaicism of this kind has been previously reported for several Cre recombinase lines20–24, including 
some directing myocardial expression25. It can also be background-dependent22. Myh6-cre appears to be effi-
cient26, but there is some reported mosaicism in the timing of its expression27 that may be relevant. However, even 
if present, metabolic heterogeneity of cardiomyocytes may not have a major functional effect28.
Another possibility is that constitutive AOX expression from even before fertilization enables energy metab-
olism to be epigenetically adapted to its presence29. In contrast, Myh6-cre is only expressed when the adult-type 
myosin heavy chain 6 would normally start to replace the fetal-type myosin heavy chain 7. Thus, AOX would be 
expressed in cardiomyocytes only from late fetal stages on, which may conflict with the epigenetic programming 
of metabolism set earlier in development.
perspectives. Although a key finding of the current study, it is difficult to follow up on the observation that 
hyperoxia counteracts heart failure in the Mcp1 mouse, without recourse to the kinds of genetic models described 
here. However, combining it with cell-specific activation of AOX, deletion of CCR2 and manipulation of other 
oxygen-sensitive enzymes and cytokines should now be a useful approach, helping to define where it acts and by 
what mechanism. One attractive idea is that Mcp1 induces a hypoxia-like response, for example by HIF activation, 
and this is counteracted by high oxygen levels, but not by AOX. In principle, this should be testable. Another possi-
bility, consistent with this idea and with our observation that Mcp1 does provoke a clear respiratory defect (Fig. 5), is 
that inhibition or down-regulation of cIII + cIV is accompanied by a down-regulation also of cI. In a previous study 
of cells cultured in glucose-rich medium we inferred precisely such a process, resulting from drug-inhibition of cIII 
or cIV, leading to a shutdown of cI which AOX was unable to relieve30. We inferred that an unknown signal emanat-
ing directly from cIII or cIV must impose such a regulation on cI, rather than simply the interruption of respiratory 
electron flow to oxygen. Introducing a by-pass of cI via the alternative NADH dehydrogenase Ndi1 from yeast was 
1 0Scientific RepoRtS |         (2019) 9:12741  | https://doi.org/10.1038/s41598-019-49231-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
able to overcome this blockade30. However, implementing both by-passes simultaneously in the Mcp1 model in vivo 
is very unlikely to succeed, since it would completely short-circuit mitochondrial ATP production. Although it can 
work in cultured cells, it failed in an OXPHOS disease model in Drosophila31, instead producing lethality. To test it 
in the Mcp1 mouse we would need first to elucidate its mechanistic basis in cultured cells, then target the relevant 
molecular machinery. The action of Mcp1 is evidently complex, and will require much deeper knowledge of mac-
rophage as well as cardiomyocyte biology, before its roles in cardiac disease can be properly understood.
Methods
Laboratory animals, procedures and ethical permits. Transgenic mice overexpressing Mcp1 specif-
ically in cardiomyocytes, directed by the Myh6 (Myhca) promoter32, here described as ‘Mcp1 mice’, were sup-
plied by Pappachan Kolattukudy, University of Central Florida. Cox10fl/fl mice33 were supplied by Carlos Moraes, 
University of Miami. Mice expressing Myh6-cre (Stock No: 011038) and ACTB-cre (Stock No: 019099) were 
purchased from Jackson Laboratories. For the initial immunohistochemistry and hyperoxia experiments, Mcp1 
mice were maintained in the original background (FVB) in which they were supplied, using non-transgenic FVB 
littermates as controls. For all other experiments, Mcp1, Cox10fl/fl, Myh6-cre and ACTB-cre mice were back-
crossed over ≥8 generations to C57Bl6/JOlaHsd (Envigo), in which the previously described AOXRosa26 strain10 
was also maintained. SNAPf-AOX mice, containing a floxed SNAP-tag expression cassette upstream of the AOX 
coding region as described in this paper, were created and backcrossed to strain C57Bl6/JOlaHsd using essentially 
the same methods as described previously for the AOXRosa26 mice10. All animals were maintained and treated 
according to the regulations of the competent animal welfare agencies, and all of the experimental protocols 
were approved according to the following permits: for experiments conducted in Germany, Regierungspräsidium 
Darmstadt (animal handling permit V54-19c20/15-B2-293) and for experiments conducted in Finland, ELLA 
(Animal Experimental Board in Finland, ethical permit: ESAVI/8766/04.10.07/2015). Mice were housed in a 
humidity and temperature-regulated animal facility with food and water provided ad libitum, and were eutha-
nized at the end of the experiment by cervical dislocation, in some cases with prior exposure to CO2. Humane end 
points were followed as described in the animal permits but, in addition, signs of prolonged immobility and/or 
consistent body shivers were considered as indicators of severe stress and the mice were duly terminated. Except 
where stated, experiments used males only, in order to minimize the total number of animals required. To test 
the effects of hyperoxia, mice were transferred at 12 weeks of age to an 85% O2 environment in a closed chamber, 
alternating at 24 h intervals with ambient air34 (see Fig. 1A).
Behavioral and physiological analyses. Cardiac function was assessed by MRI35 using OsiriX software 
(Pixmeo), or by echocardiography using a Vevo 2100 imager10, as indicated in the relevant figures. Body weight 
measurement and endurance (treadmill) experiments were performed as previously described10, except that, for 
the treadmill procedure, the total distance run was recorded instead of time, although the experimental setup was 
otherwise identical.
Genotyping. All animals used in the experiments were PCR-genotyped for all relevant loci, using crude 
ear-punch DNA as described previously10, with the primer sets indicated in Table S8.
transmission electron microscopy. A small piece of left ventricle (from mice of both sexes) was excised 
and stored at 4 °C in a buffer containing 1.5% glutaraldehyde, 1.5% formaldehyde, 0.15 M HEPES/KOH, pH 
7.4 until embedding and sectioning. For epoxy resin embedding, the samples were post-fixed in 1% osmium 
tetroxide, stained en bloc in half-saturated uranyl acetate, dehydrated in an ascending ethanol series and finally 
embedded in Agar 100 (Agar Scientific Ltd). Ultrathin sections (60–70 nm) were cut using an Ultracut E ultra-
microtome (Leica-Reichert) and examined by transmission electron microscopy (Zeiss EM900 digital). Digital 
images were captured with a slow-scan 2 K CCD camera (TRS, Moorenweis, Germany). For each animal, images 
were generated from 2–3 sections from each of 2 heart-tissue blocks, using 3 individual animals of each genotype. 
An alternative procedure used in some experiments involved fixation in 3% glutaraldehyde buffered with 0.1 M 
sodium cacodylate, embedding in Epon medium (Sigma-Aldrich) and staining with uranyl acetate and lead cit-
rate. These samples were viewed and photographed in a Philips CM 10 electron microscope.
immunohistochemistry. Tissue samples were snap-frozen and stored in liquid N2 until cryo-sectioning. 
Sections were stained for LC3 (Cell Signaling antibody #2775), and counterstained for DNA with DAPI (Bioquest 
#17507) and for F-actin with phalloidin (Sigma-Aldrich #P5282). Sections were imaged using a Leica SP2 
laser-scanning confocal microscope.
RnA isolation and qRtpcR. Total RNA was extracted from left ventricle tissue using bead homogenization 
in 1 ml (>10 volumes) of TRIzol reagent (Ambion). After incubation for 10 min at room temperature, samples were 
gently extracted with 0.2 volumes of chloroform and centrifuged at 12,000 gmax for 15 min at 4 °C. The upper (aque-
ous) phase was collected and RNA precipitated with an equal volume of isopropanol, followed by centrifugation at 
12,000 gmax for 15 min at 4 °C. The pellet was washed with 70% ethanol, air dried, resuspended in 20 μl nuclease-free 
water and quantified by NanoDrop spectrophotometry (ThermoFisher Scientific). Samples were DNase treated and 
reverse transcribed using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (ThermoFisher Scientific), 
following the manufacturer’s recommended procedure. The final 20 μl reaction volume was diluted 1:10 with 
nuclease-free water and 5 μl aliquots were used for qRTPCR, using the primers listed in Table S8 and the SensiFAST 
SYBR® No-ROX kit (Bioline), with initial denaturation at 95 °C for 2 min, followed by 40 cycles of denaturation 
(95 °C, 5 s), annealing and synthesis (60 °C, 30 s). After checking melting curves, samples were analyzed using a plate 
reader and RNA levels computed, applying the ddCT algorithm where CT values were first normalized to those of 
housekeeping gene Rps18 gene, then to the wild-type control, and finally used as exponents to generate 2−ddCT.
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protein extraction and Western blotting. Protein isolation and Western blotting were conducted 
essentially as described previously10. 10 μg protein aliquots were electrophoresed on 4–20% TGX stain-free gels 
(Bio-Rad) and transferred to PVDF membranes using Trans-Blot® TurboTM PVDF Transfer pack (Bio-Rad). 
Primary antibodies and their dilutions were as specified previously10, plus the following: porin (Abcam ab15895, 
rabbit polyclonal, 1:1,000), OXPHOS cocktail (Abcam ab110413, formerly Mitosciences ms604, mouse mono-
clonals for single subunits of each OXPHOS complex, namely NDUFB8, SDHB, UQCRC2, MTCOI and ATP5A, 
1:250), AOX (21st Century Biochemicals, customized rabbit polyclonal, 1:40,000), HSP60 (Abcam ab46798, rab-
bit polyclonal, 1:20,000), GAPDH (Cell Signaling #2118, rabbit polyclonal, 1:1,000) and LC3b (Novus NB600-
1384, rabbit polyclonal, 1:1,000). Secondary antibodies and their dilutions were: goat anti-mouse IgG (Jackson 
ImmunoResearch #115-035-146, 1:10,000) and goat anti-rabbit IgG (Jackson ImmunoResearch #111-035-144, 
1:20,000). Blot images have been cropped, rotated and framed where appropriate, and optimized for contrast and 
brightness, with reprobings of the same gel or different regions of the same gel shown as distinct image panels 
separated by white spacers. No other manipulations were introduced.
Mitochondrial isolation and respirometry. Mitochondria were isolated from heart and used for 
respirometry, essentially as described previously10. Flux values [pmol O2/(s × ml)] obtained from the traces 
were normalized to the amount of mitochondrial protein. The activity of AOX (in samples derived from 
AOX-expressing animals only), as well that of cytochrome c oxidase in all samples, was verified, even though 
these measurements are not shown in the figures.
Assays of the reduction state of ubiquinone (CoQ). The ratio of reduced to oxidized CoQ was deter-
mined by a rapid lipid extraction method. 10 to 15 mg of heart tissue (both sexes) was homogenized with a 
manual micro-pestle in 20 mM potassium phosphate buffer, pH 7.5. Debris was removed by maximum speed cen-
trifugation at 4 °C. 100 μl of sample was mixed by vortexing with 330 μl of n-propanol in the presence of 0.5 mM 
β-mercaptoethanol. After a further centrifugation at maximum speed to remove any remaining debris the clean 
lipid extracts were injected into a reverse-phase Beckmann 166 HPLC system, equipped with a C18 column (5 
μm, 150 × 4.6 mm) and column oven set up at 40 °C. The mobile phase, flow rate and gradient settings were as 
described previously36. CoQ detection was performed by a Coulochem III ESA electrochemical detector linked 
to the HPLC system, and conditioning cell was set up before the injection valve in order to maintain the oxidation 
state of the sample analytes. For redox status analysis, oxidized and reduced peaks of both CoQ9 and CoQ10 were 
quantified and their ratio calculated. Commercial CoQ6 was used as an internal standard in all runs.
Metabolite analysis. Food was withdrawn 4–6 h before the experiment, whilst water supply ad libitum was 
maintained. Mice (both sexes) were anesthetized with 4% isoflurane before injecting either U-13C6 labeled (CLM-
1396, Larodan) or 12C6 (492167, Sigma-Aldrich) glucose solution (2 g/kg bodyweight). 15 min after injection, 
mice were sacrificed by cervical dislocation and a piece of left ventricle tissue was collected and snap-frozen in 
liquid nitrogen. All samples were stored at −80 °C until processing.
Frozen heart tissues were homogenized in 1 ml cold (−80 °C) 80% methanol on dry ice. After clarification 
by centrifugation for 5 min at 4 °C, the supernatant was transferred to an Eppendorf tube. The remaining pellet 
was resuspended in RIPA protein lysis buffer and protein concentration was determined (by the BCA method). 
A fraction of the supernatant corresponding to 5 μg protein from each sample was transferred to a glass vial and 
5 nmol norvaline was added as an internal control. Metabolite extracts were dried using an EZ-2 Elite evapo-
rator (SP Scientific) and stored at −80 °C. Samples were analyzed with an UltiMate 3000RSLC HPLC (Thermo 
Scientific) coupled to a Q Exactive mass spectrometer (Thermo Scientific). After resuspension in 50% acetoni-
trile, one-tenth of each sample was loaded onto a Luna NH2 (3 μm 100 A, 150 mm × 2 mm, Phenomenex) col-
umn. Separation was achieved using (A) 5 mM ammonium acetate (pH 9.9) and (B) acetonitrile at a flowrate 
of 200 μl/min. A gradient from 15% to 95% of (A) over 18 min was utilized, followed by an isocratic step at 
95% (A) for 9 min and re-equilibration to the initial 15% (A) for 7 min. The Q Exactive was run with polarity 
switching (+3.50 kV/−3.50 kV) in full-scan mode with an m/z range of 65–975. Metabolites were quantified with 
TraceFinder 4.1 (ThermoFisher Scientific) using accurate mass measurements (≤3 ppm) and expected retention 
times established with pure standards. Data analysis, including principal component analysis and hierarchical 
clustering was performed using in-house scripts in the statistical language R. Statistical differences were deter-
mined by one-way ANOVA testing.
Statistical analysis. Data groups were compared by one-way ANOVA, with post hoc Tukey HSD (mul-
tiple comparisons) test or, where, two factors were considered, by two-way ANOVA, followed by post hoc 
Tukey HSD (multiple comparisons) test where interaction was detected or where more than two levels were 
considered for a given significant factor. Survival curves were compared by the log-rank (Mantel-Cox) and 
Gehan-Brewslow-Wilcoxon tests, all using GraphPad Prism software. The significance of progeny-class numbers 
obtained in Cox10 crosses was assessed by the chi-squared test with Yates’ correction for continuity, implemented 
using an online tool37. Statistical analyses presented in Supplementary Tables give exact p values, which are gener-
ally quoted in figures and legends using a conventional *, **, *** nomenclature to denote appropriate thresholds.
Data Availability
The authors are willing to share all materials reported in this paper for academic or non-profit research. All data 
generated or analysed during this study are included in this published article (and its Supplementary Information 
files); source data is freely available on request.
1 2Scientific RepoRtS |         (2019) 9:12741  | https://doi.org/10.1038/s41598-019-49231-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
References
 1. Gu, L. et al. In vivo properties of monocyte chemoattractant protein-1. J. Leukoc. Biol. 62, 577–580 (1997).
 2. Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon 
Cytokine Res. 29, 313–326 (2009).
 3. Frangogiannis, N. G., Smith, C. W. & Entman, M. L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53, 31–47 
(2002).
 4. Martire, A. et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic 
preconditioning through SAPK/JNK1/2 activation. Cardiovasc. Res. 57, 523–534 (2003).
 5. Morimoto, H. et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction 
and remodeling after myocardial infarction. Circ. Res. 99, 891–899 (2006).
 6. Hayashidani, S. et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after 
experimental myocardial infarction. Circulation 108, 2134–2140 (2003).
 7. Yndestad, A. et al. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236–241 (2007).
 8. Kolattukudy, P. E. & Niu, J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/
CCR2 pathway. Circ. Res. 110, 174–189 (2012).
 9. Younce, C. W. & Kolattukudy, P. E. MCP-1 causes cardiomyoblast death via autophagy resulting from ER stress caused by oxidative 
stress generated by inducing a novel zinc-finger protein, MCPIP. Biochem. J. 426, 43–53 (2010).
 10. Szibor, M. et al. Broad AOX expression in a genetically tractable mouse model does not disturb normal physiology. Dis. Models 
Mech. 10, 163–171 (2017).
 11. Dry, I. B., Moore, A. L., Day, D. A. & Wiskich, J. T. Regulation of alternative pathway activity in plant mitochondria: nonlinear 
relationship between electron flux and the redox poise of the quinone pool. Arch. Biochem. Biophys. 273, 148–157 (1989).
 12. Hoefnagel, M. H. N. & Wiskich, J. T. Activation of the plant alternative oxidase by high reduction levels of the Q-Pool and pyruvate. 
Arch. Biochem. Biophys. 355, 262–270 (1998).
 13. Dogan, S. A. et al. Perturbed redox signaling exacerbates a mitochondrial myopathy. Cell Metab. 28, 764–775 (2018).
 14. El-Khoury, R. et al. Alternative oxidase expression in the mouse enables bypassing cytochrome c oxidase blockade and limits 
mitochondrial ROS overproduction. PLoS Genet. 9, e1003182 (2013).
 15. Rajendran, J. et al. Expression of alternative oxidase prevents lethal mitochondrial cardiomyopathy in a mouse model of complex III 
deficiency. EMBO Mol. Med. 11, e9456 (2019).
 16. Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. 
Cell 167, 457–470.
 17. Regoes, A. & Hehl, A. B. SNAP-tag mediated live cell labeling as an alternative to GFP in anaerobic organisms. BioTechniques 
39(809–810), 812 (2005).
 18. Pugach, E. K., Richmond, P. A., Azofeifa, J. G., Dowell, R. D. & Leinwand, L. A. Prolonged Cre expression driven by the α-myosin 
heavy chain promoter can be cardiotoxic. J. Mol. Cell. Cardiol. 86, 54–61 (2015).
 19. Shi, J., Hua, L., Harmer, D., Li, P. & Ren, G. Cre driver mice targeting macrophages. Methods Mol Biol. 1784, 263–275 (2018).
 20. Bergqvist, I., Eriksson, B., Eriksson, M. & Holmberg, D. Transgenic Cre recombinase expression in germ cells and early 
embryogenesis directs homogeneous and ubiquitous deletion of loxP-flanked gene segments. FEBS Lett. 438, 76–80 (1998).
 21. Le, Y. Z. et al. Mouse opsin promoter-directed Cre recombinase expression in transgenic mice. Mol. Vis. 12, 389–398 (2006).
 22. Iacovelli, J. et al. Generation of Cre transgenic mice with postnatal RPE-specific ocular expression. Invest. Ophthalmol. Vis. Sci. 52, 
1378–1383 (2011).
 23. Bao, J., Ma, H. Y., Schuster, A., Lin, Y. M. & Yan, W. Incomplete cre-mediated excision leads to phenotypic differences between Stra8-
iCre; Mov10l1(lox/lox) and Stra8-iCre; Mov10l1(lox/Δ) mice. Genesis 51, 481–490 (2013).
 24. Frenz, S. et al. Mosaic pattern of Cre recombinase expression in cochlear outer hair cells of the Brn3.1 Cre mouse. Neuroreport 26, 
309–313 (2015).
 25. Breckenridge, R., Kotecha, S., Towers, N., Bennett, M. & Mohun, T. Pan-myocardial expression of Cre recombinase throughout 
mouse development. Genesis 4, 135–144 (2007).
 26. Yin, Z. et al. Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 117, 1414–1422 
(2008).
 27. Zhu, Y. et al. Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth. PLoS One 8, 
e54221 (2013).
 28. Villa Del Campo, C., Clavería, C., Sierra, R. & Torres, M. Cell competition promotes phenotypically silent cardiomyocyte 
replacement in the mammalian heart. Cell Rep. 8, 1741–1751 (2014).
 29. Etchegaray, J. P. & Mostovslavsky, R. Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. 
Mol. Cell 62, 695–711 (2016).
 30. Cannino, G. et al. Glucose modulates respiratory complex I activity in response to acute mitochondrial dysfunction. J. Biol. Chem. 
287, 38729–38740 (2012).
 31. Kemppainen, K. K., Kemppainen, E. & Jacobs, H. T. The alternative oxidase AOX does not rescue the phenotype of tko25t mutant 
flies. G3 (Bethesda) 4, 2013–2021 82014).
 32. Kolattukudy, P. E. et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am. J. Pathol. 152, 
101–111 (1998).
 33. Diaz, F., Thomas, C. K., Garcia, S., Hernandez, D. & Moraes, C. T. Mice lacking COX10 in skeletal muscle recapitulate the phenotype 
of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum Mol Genet. 14, 2737–2748 (2005).
 34. Alejandre-Alcázar, M. A. et al. Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. 
Am. J. Physiol. Lung Cell Mol. Physiol. 292, L537–L549 (2007).
 35. Ziebart, T. et al. Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function 
after ischemia. Circ. Res. 103, 1327–1334 (2008).
 36. Rodríguez-Aguilera, J. C., Cortés, A. B., Fernández-Ayala, D. J. & Navas, P. Biochemical assessment of Coenzyme Q10 deficiency. J. 
Clin. Med. 6, 27 (2017).
 37. Preacher, K. J. Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and 
independence [Computer software], http://quantpsy.org (2001).
Acknowledgements
We thank Carlos Moraes and Pappachan Kolattukudy for supply of mouse lines, Riikka Kivelä for access to 
and advice with the Vevo 2100 instrument and analytical software for echocardiography, Sava Kostin for 
immunohistochemistry and for electron microscopy shown in Fig. 1, Gerhard Kripp for assistance with the 
electron microscopy shown in Fig. 5, Svetlana Konovalova (for providing materials and advice on the oxyblot 
method), Maarit Partanen, Maria Arrano de Kivikko, Tuula Manninen, Babette Hollmann, Markus Innilä, 
Tea Tuomela, Eveliina Teeri, Ursula Hofmann and Ana Belén Cortés for technical advice and assistance, and 
Anu Suomalainen for providing lab space and equipment. We thank Orian Shirihai and Eric Dufour for many 
13Scientific RepoRtS |         (2019) 9:12741  | https://doi.org/10.1038/s41598-019-49231-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
useful discussions and Troy Faithfull for advice with the manuscript. This work was supported by the European 
Research Council [Advanced Grant 232838] Academy of Finland [grant numbers 283157 and 272376]; Tampere 
University Hospital Medical Research Fund, the Sigrid Juselius Foundation and ISCIII [Spanish government, FIS 
grant PI17-01286]. PKD was also supported by personal grants from the Maud Kuistila Memorial Foundation, 
Sydäntutkimussäätiö and Orion Research foundation.
Author contributions
M.Sz., T.B. and P.K.D. jointly conceived the study, which was supervised by H.T.J., T.B., R.E.M., G.B.-C., T.G. and 
M.Sz. P.K.D. performed the experiments and analyses, together with A.W., U.G., K.S., JtH.-S., G.J.S. and I.M.B.-M. 
P.K.D., M.Sz. and H.T.J. compiled the figures and H.T.J. drafted the manuscript, which was finalized by all authors. 
Apart from the first author and three senior authors, all others are listed alphabetically by surname.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-49231-9.
Competing Interests: MSz is a shareholder in a startup company aiming to develop therapeutics based on 
AOX. All other authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
